NCT04646889 is a Phase 1 clinical trial of AR882 Single Dose in Renal Impairment, sponsored by Arthrosi Therapeutics.

Who is sponsoring NCT04646889?

NCT04646889 is sponsored by Arthrosi Therapeutics.

What drugs are being tested in NCT04646889?

Interventions in NCT04646889: AR882 Single Dose, AR882 Multiple Dose.

What condition does NCT04646889 study?

NCT04646889 studies Renal Impairment.

Is NCT04646889 still recruiting?

NCT04646889 is currently completed. Last updated 5 August 2022.

Last reviewed 2022-08-05 · How we verify

NCT04646889

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

Completed Phase 1 Last updated 5 August 2022

What this trial tests

Phase 1 trial testing AR882 Single Dose in Renal Impairment in 46 participants. Completed in 27 June 2022.

Timeline

14 January 2021

Primary endpoint
27 June 2022

27 June 2022

Quick facts

Lead sponsor	Arthrosi Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	14 January 2021
Primary completion	27 June 2022
Estimated completion	27 June 2022
Sites	4 locations across New Zealand, United States

Drugs / interventions tested

AR882 Single Dose — full drug profile →
AR882 Multiple Dose — full drug profile →

Conditions studied

Renal Impairment — all drugs for Renal Impairment →

Sponsor

Arthrosi Therapeutics — full company profile →

Who can join

Adults 18 to 75, any sex, with Renal Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 2-segment, multi-center, phase 1, open-label, study evaluating the pharmacokinetics and pharmacodynamics of AR882 in subjects with various degrees of renal impairment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Review of Urate-Lowering Therapeutics: From the Past to the Future.
Jenkins C, Hwang JH, Kopp JB, Winkler CA, et al · · 2022 · cited 38× · PMID 36081938 · DOI 10.3389/fphar.2022.925219

Verify or expand the search:

Other recruiting trials for Renal Impairment

Currently open trials in the same condition.

NCT07348237 — A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) · Phase 1 · recruiting
NCT07315360 — A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function · Phase 1 · recruiting
NCT07217886 — A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls · Phase 1 · recruiting
NCT07154901 — Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD23 · Phase 1 · recruiting
NCT07017933 — Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes · NA · recruiting

Other Arthrosi Therapeutics trials

Trials by the same sponsor.

NCT05253833 — Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout · Phase 2 · completed
NCT05119686 — Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients · Phase 2 · completed
NCT04508426 — Single-dose AME Study With [14C]AR882 in Healthy Male Subjects · Phase 1 · completed
NCT04155918 — Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients · Phase 2 · completed
NCT04314986 — Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04646889 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arthrosi Therapeutics
Last refreshed: 5 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04646889.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing